Michelle Gomes
Michelle Gomes has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Kalina Mihaylova
Anne’s Day Ltd (Daye)
5 shared publicationsValentina Milanova
Anne’s Day Ltd (Daye)
5 shared publicationsJan Multmeier
TotaEffects GmH
4 shared publications- Hannah McCulloch
Independent Consultant
3 shared publications Hana McMahon
Center for Reproductive Health, University of Edinburgh
2 shared publicationsIva Lazarova
Anne’s Day Ltd, London, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published by Frontiers Media SA in Frontiers in Network Physiology
- Vol. 6, 1799486
Predictive modeling for cervical cancer: existing AI approaches and the emerging role of vaginal microbiome
Cervical cancer remains a major global health burden, yet current screening tools lack precision in identifying which women with high-risk human papillomavirus (HPV) infection will progress to high-grade lesions or cancer. Within a network-physiology framework, cervical carcinogenesis is viewed as emerging from dynamic interactions between viral dynamics, host immunity, vaginal ecology, vaccination status and behaviour rather than from isolated risk factors. This perspective review examines artificial intelligence (AI) approaches for cervical cancer prediction and evaluates the emerging role of the vaginal microbiome as a complementary biomarker within these interconnected physiological networks. The review synthesises evidence linking non-Lactobacillus-dominated or Lactobacillus iners-rich vaginal communities with increased HPV persistence and cervical intraepithelial neoplasia, contrasted with protective Lactobacillus crispatus-dominant communities, and outlines how these ecological signatures could be combined with HPV genotype and clinical factors in multi-modal models. A structured narrative synthesis of published AI tools demonstrates that current prognostic, diagnostic and screening algorithms rely mainly on demographic, clinical or imaging variables, with no validated models yet integrating vaginal microbiome profiles into cervical cancer risk calculators. The manuscript proposes a technical framework for microbiome-enabled modelling, covering feature engineering from community state types, algorithm selection, handling of high-dimensional omics data, and staged validation in NHS-relevant populations. Finally, it outlines a translational pathway for embedding microbiome-informed risk models into cervical screening using self-collected tampon sampling, AI-driven triage and digital decision support, and identifies key unmet needs, including longitudinal multi-omic cohorts, international consortia and robust bias auditing.
- 5 June 2026
- Published by Frontiers Media SA in Frontiers in Network Physiology
- Vol. 6, 1799486
Open AccessPredictive modeling for cervical cancer: existing AI approaches and the emerging role of vaginal microbiome
Cervical cancer remains a major global health burden, yet current screening tools lack precision in identifying which women with high-risk human papillomavirus (HPV) infection will progress to high-grade lesions or cancer. Within a network-physiology framework, cervical carcinogenesis is viewed as emerging from dynamic interactions between viral dynamics, host immunity, vaginal ecology, vaccination status and behaviour rather than from isolated risk factors. This perspective review examines artificial intelligence (AI) approaches for cervical cancer prediction and evaluates the emerging role of the vaginal microbiome as a complementary biomarker within these interconnected physiological networks. The review synthesises evidence linking non-Lactobacillus-dominated or Lactobacillus iners-rich vaginal communities with increased HPV persistence and cervical intraepithelial neoplasia, contrasted with protective Lactobacillus crispatus-dominant communities, and outlines how these ecological signatures could be combined with HPV genotype and clinical factors in multi-modal models. A structured narrative synthesis of published AI tools demonstrates that current prognostic, diagnostic and screening algorithms rely mainly on demographic, clinical or imaging variables, with no validated models yet integrating vaginal microbiome profiles into cervical cancer risk calculators. The manuscript proposes a technical framework for microbiome-enabled modelling, covering feature engineering from community state types, algorithm selection, handling of high-dimensional omics data, and staged validation in NHS-relevant populations. Finally, it outlines a translational pathway for embedding microbiome-informed risk models into cervical screening using self-collected tampon sampling, AI-driven triage and digital decision support, and identifies key unmet needs, including longitudinal multi-omic cohorts, international consortia and robust bias auditing.
- Open Access
Acceptability of diagnostic tampon self-sampling for HPV: Mixed methods findings from the STAMP Trial and focus groups
Background Multiple barriers limit access to traditional in-person clinician sampling for cervical cancer. The STAMP (Screening with Tampons: Evaluating Diagnostic Accuracy for HPV and Assessing Participant Views) study evaluated the diagnostic accuracy and acceptability of tampon-based self-sampling for HPV amongst people assigned female at birth. Encouraging technical performance of the tampon as a sample for microbial detection was observed relative to clinician-taken samples. Pre and post trial questionnaires and a nested qualitative study explored acceptability. Methods All participants (n=263) completed questionnaires before and after sampling using three methods: tampon-based self-sampling, swab-based self-sampling, and clinician-collected samples. Questions included comfort, trust and ease of use of tampon-sampling. Four focus groups (n=24) were conducted online, and analysed using reflexive thematic analysis. Results Questionnaire responses suggested tampon-based self-sampling was highly acceptable. Qualitative analysis identified four key themes: advantages of self-sampling over clinician-sampling; unique benefits of tampon-based self-sampling; concerns about accuracy and trust; and confidence in correct use. Participants valued the physical comfort, psychological ease, and practical convenience of self-sampling compared to clinician-sampling. The familiarity of tampons as an everyday product was central to acceptability, normalising screening. While some initially questioned accuracy, most were reassured by evidence of performance. Clear instructions and understanding the evidence base boosted confidence. Conclusion Findings suggest that tampon-based self-sampling is a highly acceptable alternative sampling approach for cervical screening that may increase screening participation by addressing multiple barriers. Implementation strategies should emphasise the method’s everyday nature, while providing accessible guidance to support correct usage. What is already known on this topic Self-sampling for Human Papillomavirus (HPV) has been recommended by the World Health Organisation as an additional approach to expand cervical cancer screening services, complementing conventional clinician-taken sampling to broaden access and address barriers associated with in-person care. What this study adds Findings from this study suggest that self-sampling has the potential to support screening for cervical cancer as an acceptable, at-home approach addressing physical, psychological and practical barriers associated with traditional clinician collected sampling. Participants reported that the familiarity of using a tampon for self-sampling creates a unique advantage over other self-sampling methods through demedicalising and normalising screening, therefore potentially increasing accessibility and participation among underscreened populations who experience most barriers. How this study might affect research, practice or policy Self-sampling including tampon-based self sampling offers a promising, acceptable approach to achieving cancer elimination goals. Implementation of tampon-based self-sampling for HPV should be clear, comprehensive and accessible, incorporating visual aids and simple language while emphasising the rationale and scientific evidence behind the collection method
Open AccessAcceptability of diagnostic tampon self-sampling for HPV: Mixed methods findings from the STAMP Trial and focus groups
Background Multiple barriers limit access to traditional in-person clinician sampling for cervical cancer. The STAMP (Screening with Tampons: Evaluating Diagnostic Accuracy for HPV and Assessing Participant Views) study evaluated the diagnostic accuracy and acceptability of tampon-based self-sampling for HPV amongst people assigned female at birth. Encouraging technical performance of the tampon as a sample for microbial detection was observed relative to clinician-taken samples. Pre and post trial questionnaires and a nested qualitative study explored acceptability. Methods All participants (n=263) completed questionnaires before and after sampling using three methods: tampon-based self-sampling, swab-based self-sampling, and clinician-collected samples. Questions included comfort, trust and ease of use of tampon-sampling. Four focus groups (n=24) were conducted online, and analysed using reflexive thematic analysis. Results Questionnaire responses suggested tampon-based self-sampling was highly acceptable. Qualitative analysis identified four key themes: advantages of self-sampling over clinician-sampling; unique benefits of tampon-based self-sampling; concerns about accuracy and trust; and confidence in correct use. Participants valued the physical comfort, psychological ease, and practical convenience of self-sampling compared to clinician-sampling. The familiarity of tampons as an everyday product was central to acceptability, normalising screening. While some initially questioned accuracy, most were reassured by evidence of performance. Clear instructions and understanding the evidence base boosted confidence. Conclusion Findings suggest that tampon-based self-sampling is a highly acceptable alternative sampling approach for cervical screening that may increase screening participation by addressing multiple barriers. Implementation strategies should emphasise the method’s everyday nature, while providing accessible guidance to support correct usage. What is already known on this topic Self-sampling for Human Papillomavirus (HPV) has been recommended by the World Health Organisation as an additional approach to expand cervical cancer screening services, complementing conventional clinician-taken sampling to broaden access and address barriers associated with in-person care. What this study adds Findings from this study suggest that self-sampling has the potential to support screening for cervical cancer as an acceptable, at-home approach addressing physical, psychological and practical barriers associated with traditional clinician collected sampling. Participants reported that the familiarity of using a tampon for self-sampling creates a unique advantage over other self-sampling methods through demedicalising and normalising screening, therefore potentially increasing accessibility and participation among underscreened populations who experience most barriers. How this study might affect research, practice or policy Self-sampling including tampon-based self sampling offers a promising, acceptable approach to achieving cancer elimination goals. Implementation of tampon-based self-sampling for HPV should be clear, comprehensive and accessible, incorporating visual aids and simple language while emphasising the rationale and scientific evidence behind the collection method
- Open Access
- 14 May 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (5) , e0185224
Diagnostic accuracy of the Daye diagnostic tampon compared to clinician-collected and self-collected vaginal swabs for detecting HPV: a comparative study
Cervical cancer screening is vital for achieving global elimination of this preventable disease. Vaginal self-sampling (VSS) for human papillomavirus (HPV) has the potential to increase screening uptake, particularly among individuals who may be underserved by clinician collection. Expanding self-sampling options with accurate, acceptable collection devices is essential. The Daye diagnostic tampon (DDT) offers an innovative approach, utilizing a tampon for HPV-based detection. This study assessed the diagnostic accuracy of DDT in detecting high-risk HPV infections, using vaginal clinician-collected swabs (CCS) as the reference standard. In this UK-based study, 260 participants provided CCS and VSS (with Copan FLOQSwabs) and DDT samples for HPV testing. Samples were analyzed using the Aptima HPV assay, which detects 14 high-risk HPV types. The sensitivity, specificity, positive predictive value, and negative predictive value of the DDT were evaluated against the CCS. Invalidity rates—HPV-negative results with negative internal controls—were compared across sampling methods. The DDT showed a sensitivity of 82.9% [95% confidence interval (CI): 72.4%–89.9%], specificity of 91.6% (CI: 86.4%–94.9%), and overall accuracy of 89.0% (CI: 84.4%–92.4%) relative to CCS. McNemar’s test showed no significant difference between CCS and DDT results ( P = 0.845). Valid result rates were highest for DDT (99.2%), followed by VSS (95.4%) and CCS (90.8%). The DDT demonstrates comparable accuracy to CCS for detecting high-risk HPV. This novel device shows promise as a self-sampling method. Furthermore, complementary research should focus on assessing DDT’s clinical performance in detecting HPV associated with cervical disease endpoints. IMPORTANCE: Cervical cancer remains a leading preventable cause of cancer death globally, with persistent disparities in screening access. Self-sampling for HPV has emerged as a critical tool to improve screening uptake, particularly among underserved populations, yet device acceptability and diagnostic reliability remain barriers to equitable implementation. This study demonstrates that the Daye diagnostic tampon (DDT), a novel, tampon-based self-sampling method, achieves diagnostic accuracy comparable to clinician-collected swabs (sensitivity 82.9% and specificity 91.6%) while yielding fewer invalid results (0.8%) than conventional swabs. By aligning with a familiar menstrual product, the DDT addresses usability concerns that hinder confidence in existing self-sampling devices, as evidenced by 70.5% participant preference in focus groups. These findings advance progress toward World Health Organisation (WHO) cervical cancer elimination targets by validating a culturally resonant, high-performance alternative to clinic-based sampling. The DDT’s potential to expand screening access, especially in low-resource settings or among individuals avoiding pelvic exams, could transform preventive care landscapes, reducing disparities in a disease rooted in healthcare inequity.
- 14 May 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (5) , e0185224
Open AccessDiagnostic accuracy of the Daye diagnostic tampon compared to clinician-collected and self-collected vaginal swabs for detecting HPV: a comparative study
Cervical cancer screening is vital for achieving global elimination of this preventable disease. Vaginal self-sampling (VSS) for human papillomavirus (HPV) has the potential to increase screening uptake, particularly among individuals who may be underserved by clinician collection. Expanding self-sampling options with accurate, acceptable collection devices is essential. The Daye diagnostic tampon (DDT) offers an innovative approach, utilizing a tampon for HPV-based detection. This study assessed the diagnostic accuracy of DDT in detecting high-risk HPV infections, using vaginal clinician-collected swabs (CCS) as the reference standard. In this UK-based study, 260 participants provided CCS and VSS (with Copan FLOQSwabs) and DDT samples for HPV testing. Samples were analyzed using the Aptima HPV assay, which detects 14 high-risk HPV types. The sensitivity, specificity, positive predictive value, and negative predictive value of the DDT were evaluated against the CCS. Invalidity rates—HPV-negative results with negative internal controls—were compared across sampling methods. The DDT showed a sensitivity of 82.9% [95% confidence interval (CI): 72.4%–89.9%], specificity of 91.6% (CI: 86.4%–94.9%), and overall accuracy of 89.0% (CI: 84.4%–92.4%) relative to CCS. McNemar’s test showed no significant difference between CCS and DDT results ( P = 0.845). Valid result rates were highest for DDT (99.2%), followed by VSS (95.4%) and CCS (90.8%). The DDT demonstrates comparable accuracy to CCS for detecting high-risk HPV. This novel device shows promise as a self-sampling method. Furthermore, complementary research should focus on assessing DDT’s clinical performance in detecting HPV associated with cervical disease endpoints. IMPORTANCE: Cervical cancer remains a leading preventable cause of cancer death globally, with persistent disparities in screening access. Self-sampling for HPV has emerged as a critical tool to improve screening uptake, particularly among underserved populations, yet device acceptability and diagnostic reliability remain barriers to equitable implementation. This study demonstrates that the Daye diagnostic tampon (DDT), a novel, tampon-based self-sampling method, achieves diagnostic accuracy comparable to clinician-collected swabs (sensitivity 82.9% and specificity 91.6%) while yielding fewer invalid results (0.8%) than conventional swabs. By aligning with a familiar menstrual product, the DDT addresses usability concerns that hinder confidence in existing self-sampling devices, as evidenced by 70.5% participant preference in focus groups. These findings advance progress toward World Health Organisation (WHO) cervical cancer elimination targets by validating a culturally resonant, high-performance alternative to clinic-based sampling. The DDT’s potential to expand screening access, especially in low-resource settings or among individuals avoiding pelvic exams, could transform preventive care landscapes, reducing disparities in a disease rooted in healthcare inequity.
- Open Access
- 26 March 2025
- Published by Springer Nature in BMC Women's Health
- Vol. 25 (1) , 1-13
Efficacy and acceptability of a self-collected medical grade tampon as a novel vaginal sample collection tool for the detection of HPV and STIs
Cervical cancer remains a significant health concern, particularly in low-income and middle-income countries (LMICs). This study aims to compare the efficacy and suitability of a self-collected tampon for the detection of human papillomavirus (HPV) and sexually transmitted infections (STIs) using qualitative TMA-based assays (Transcription Mediated Amplification; APTIMA® HPV, APTIMA® Combo 2 (CT/NG; AC2 from now on) and APTIMA®Bacterial Vaginosis (BV from now on). Additionally, we assess the acceptability of tampons as a self-collection tool. A cohort of 75 female participants aged 18–54 years was recruited through female-focused social networks. Participants provided informed consent and underwent both Health Care Workers (HCW-collected) and self-collected sample collection using the Daye Diagnostic Tampon. Samples were stored in ThinPrep Vials (TP Vial) or Aptima® Multitest Swab Collection Kit (APTIMA®) solutions. HPV and STI testing were performed using TMA-based assay on the fully automated Panther® Platform. Acceptability was assessed through a questionnaire with Likert-scale responses. The study involved 60 participants who completed the study (80% of recruited participants). The self-collected tampons showed sensitivity and specificity of 66.67% and 90.74% (when rinsed in TP Vial) and 83.33% and 85.42% (when rinsed in APTIMA®) for HPV detection, respectively. For bacterial vaginosis (BV) detection, the tampons exhibited sensitivity and specificity of 100.0% and 96.43% (TP Vial) and 88.89% and 98.04% (APTIMA), respectively. For detection of chlamydia and gonorrhoea (AC2), the sensitivity and specificity were 100.00% and 100.0% (TP Vial) and 100.00% and 98.31% (APTIMA), respectively. Participants expressed a preference for tampon self-collection over HCW-collected swabs (90%). Self-collected tampons demonstrated promising diagnostic accuracy to HCW-collected swabs for HPV and STI detection. The tampon self-collection method was well-accepted and preferred by participants, suggesting its potential as an alternative screening tool, particularly in low-resource settings. Further research with larger and more diverse populations is recommended to validate these findings and inform tampon-based self-collection programs for cervical cancer screening. Randomised controlled trials and comparisons with gold standard methods would enhance validation.
- 26 March 2025
- Published by Springer Nature in BMC Women's Health
- Vol. 25 (1) , 1-13
Open AccessEfficacy and acceptability of a self-collected medical grade tampon as a novel vaginal sample collection tool for the detection of HPV and STIs
Cervical cancer remains a significant health concern, particularly in low-income and middle-income countries (LMICs). This study aims to compare the efficacy and suitability of a self-collected tampon for the detection of human papillomavirus (HPV) and sexually transmitted infections (STIs) using qualitative TMA-based assays (Transcription Mediated Amplification; APTIMA® HPV, APTIMA® Combo 2 (CT/NG; AC2 from now on) and APTIMA®Bacterial Vaginosis (BV from now on). Additionally, we assess the acceptability of tampons as a self-collection tool. A cohort of 75 female participants aged 18–54 years was recruited through female-focused social networks. Participants provided informed consent and underwent both Health Care Workers (HCW-collected) and self-collected sample collection using the Daye Diagnostic Tampon. Samples were stored in ThinPrep Vials (TP Vial) or Aptima® Multitest Swab Collection Kit (APTIMA®) solutions. HPV and STI testing were performed using TMA-based assay on the fully automated Panther® Platform. Acceptability was assessed through a questionnaire with Likert-scale responses. The study involved 60 participants who completed the study (80% of recruited participants). The self-collected tampons showed sensitivity and specificity of 66.67% and 90.74% (when rinsed in TP Vial) and 83.33% and 85.42% (when rinsed in APTIMA®) for HPV detection, respectively. For bacterial vaginosis (BV) detection, the tampons exhibited sensitivity and specificity of 100.0% and 96.43% (TP Vial) and 88.89% and 98.04% (APTIMA), respectively. For detection of chlamydia and gonorrhoea (AC2), the sensitivity and specificity were 100.00% and 100.0% (TP Vial) and 100.00% and 98.31% (APTIMA), respectively. Participants expressed a preference for tampon self-collection over HCW-collected swabs (90%). Self-collected tampons demonstrated promising diagnostic accuracy to HCW-collected swabs for HPV and STI detection. The tampon self-collection method was well-accepted and preferred by participants, suggesting its potential as an alternative screening tool, particularly in low-resource settings. Further research with larger and more diverse populations is recommended to validate these findings and inform tampon-based self-collection programs for cervical cancer screening. Randomised controlled trials and comparisons with gold standard methods would enhance validation.
- Open Access
Diagnostic Accuracy of the Daye Diagnostic Tampon Compared to Clinician-Collected and Self-Collected Vaginal Swabs for Detecting HPV: A Comparative Study
Introduction Cervical cancer screening is vital for achieving global elimination of this preventable disease. Vaginal self-sampling (VSS) for human papillomavirus (HPV) has the potential to increase screening uptake, particularly among individuals who may be underserved by clinician collection. Expanding self-sampling options with accurate, acceptable collection devices is essential. The Daye Diagnostic Tampon (DDT) offers an innovative approach, utilising a menstrual tampon to collect vaginal and cervical fluid for HPV screening. This study assessed the diagnostic accuracy of the DDT in detecting high-risk HPV infections, using clinician-collected swabs (CCS) as the reference standard. Methods In this UK-based study, 260 participants provided CCS, VSS, and DDT samples for HPV testing. Samples were analysed using a clinically validated assay for 14 high-risk HPV types. Sensitivity, specificity, positive predictive value, and negative predictive value of the DDT were evaluated against CCS. Invalidity rates—HPV-negative results with negative internal controls—were compared across sampling methods. Results The DDT showed a sensitivity of 82.9% (95% CI:72.4–89.9%), specificity of 91.6% (CI:86.4–94.9%), and overall accuracy of 89.0% (CI:84.4–92.4%) relative to CCS. McNemar’s test showed no significant difference between CCS and DDT results (p = 0.845). Valid result rates were highest for DDT (99.2%), followed by VSS (95.4%) and CCS (90.8%). Conclusion The DDT demonstrates comparable accuracy to CCS for detecting high-risk HPV. This novel device shows promise as a self-sampling method. Further, complementary research should focus on assessing DDT’s clinical performance in detecting HPV associated with cervical disease endpoints.
Open AccessDiagnostic Accuracy of the Daye Diagnostic Tampon Compared to Clinician-Collected and Self-Collected Vaginal Swabs for Detecting HPV: A Comparative Study
Introduction Cervical cancer screening is vital for achieving global elimination of this preventable disease. Vaginal self-sampling (VSS) for human papillomavirus (HPV) has the potential to increase screening uptake, particularly among individuals who may be underserved by clinician collection. Expanding self-sampling options with accurate, acceptable collection devices is essential. The Daye Diagnostic Tampon (DDT) offers an innovative approach, utilising a menstrual tampon to collect vaginal and cervical fluid for HPV screening. This study assessed the diagnostic accuracy of the DDT in detecting high-risk HPV infections, using clinician-collected swabs (CCS) as the reference standard. Methods In this UK-based study, 260 participants provided CCS, VSS, and DDT samples for HPV testing. Samples were analysed using a clinically validated assay for 14 high-risk HPV types. Sensitivity, specificity, positive predictive value, and negative predictive value of the DDT were evaluated against CCS. Invalidity rates—HPV-negative results with negative internal controls—were compared across sampling methods. Results The DDT showed a sensitivity of 82.9% (95% CI:72.4–89.9%), specificity of 91.6% (CI:86.4–94.9%), and overall accuracy of 89.0% (CI:84.4–92.4%) relative to CCS. McNemar’s test showed no significant difference between CCS and DDT results (p = 0.845). Valid result rates were highest for DDT (99.2%), followed by VSS (95.4%) and CCS (90.8%). Conclusion The DDT demonstrates comparable accuracy to CCS for detecting high-risk HPV. This novel device shows promise as a self-sampling method. Further, complementary research should focus on assessing DDT’s clinical performance in detecting HPV associated with cervical disease endpoints.
- Open Access
- 22 January 2024
- Published by Springer Nature in Research Square
Efficacy and Acceptability of Self-Collected Medical Grade Tampon as a Novel Vaginal Sample Collection Tool for the Detection of HPV and STIs
Objective: Cervical cancer remains a significant health concern, particularly in low-income and middle-income countries (LMICs). This study aims to compare the efficacy and suitability of a self-collected tampon for the detection of human papillomavirus (HPV) and sexually transmitted infections (STIs) using qualitative TMA-based assays (Transcription Mediated Amplification; APTIMA ® HPV, APTIMA ® Combo 2 (CT/NG; AC2 from now on) and APTIMA ® Bacterial Vaginosis (BV from now on). Additionally, we assess the acceptability of tampons as a self-collection tool. Methods: A cohort of 75 female participants aged 18-54 years was recruited through female-focused social networks. Participants provided informed consent and underwent both Health Care Workers (HCW-collected) and self-collected sample collection using the Daye Diagnostic Tampon. Samples were stored in ThinPrep Vials (TP Vial) or Aptima ® Multitest Swab Collection Kit (APTIMA ®) solutions. HPV and STI testing were performed using TMA-based assay on the fully automated Panther ® Platform. Acceptability was assessed through a questionnaire with Likert-scale responses. Results: The study involved 60 participants who completed the study (80% of recruited participants). The self-collected tampons showed sensitivity and specificity of 66.67% and 90.74% (when rinsed in TP Vial) and 83.33% and 85.42% (when rinsed in APTIMA ®) for HPV detection, respectively. For bacterial vaginosis (BV) detection, the tampons exhibited sensitivity and specificity of 100.0% and 96.43% (TP Vial) and 88.89% and 98.04% (APTIMA), respectively. For detection of chlamydia and gonorrhoea (AC2), the sensitivity and specificity were 100.00% and 100.0% (TP Vial) and 100.00% and 98.31% (APTIMA), respectively. Participants expressed a preference for tampon self-collection over HCW-collected swabs (90%). Conclusion: Self-collected tampons demonstrated promising diagnostic accuracy to HCW-collected swabs for HPV and STI detection. The tampon self-collection method was well-accepted and preferred by participants, suggesting its potential as an alternative screening tool, particularly in low-resource settings. Further research with larger and more diverse populations is recommended to validate these findings and inform tampon-based self-collection programs for cervical cancer screening. Randomised controlled trials and comparisons with gold standard methods would enhance validation.
- 22 January 2024
- Published by Springer Nature in Research Square
Open AccessEfficacy and Acceptability of Self-Collected Medical Grade Tampon as a Novel Vaginal Sample Collection Tool for the Detection of HPV and STIs
Objective: Cervical cancer remains a significant health concern, particularly in low-income and middle-income countries (LMICs). This study aims to compare the efficacy and suitability of a self-collected tampon for the detection of human papillomavirus (HPV) and sexually transmitted infections (STIs) using qualitative TMA-based assays (Transcription Mediated Amplification; APTIMA ® HPV, APTIMA ® Combo 2 (CT/NG; AC2 from now on) and APTIMA ® Bacterial Vaginosis (BV from now on). Additionally, we assess the acceptability of tampons as a self-collection tool. Methods: A cohort of 75 female participants aged 18-54 years was recruited through female-focused social networks. Participants provided informed consent and underwent both Health Care Workers (HCW-collected) and self-collected sample collection using the Daye Diagnostic Tampon. Samples were stored in ThinPrep Vials (TP Vial) or Aptima ® Multitest Swab Collection Kit (APTIMA ®) solutions. HPV and STI testing were performed using TMA-based assay on the fully automated Panther ® Platform. Acceptability was assessed through a questionnaire with Likert-scale responses. Results: The study involved 60 participants who completed the study (80% of recruited participants). The self-collected tampons showed sensitivity and specificity of 66.67% and 90.74% (when rinsed in TP Vial) and 83.33% and 85.42% (when rinsed in APTIMA ®) for HPV detection, respectively. For bacterial vaginosis (BV) detection, the tampons exhibited sensitivity and specificity of 100.0% and 96.43% (TP Vial) and 88.89% and 98.04% (APTIMA), respectively. For detection of chlamydia and gonorrhoea (AC2), the sensitivity and specificity were 100.00% and 100.0% (TP Vial) and 100.00% and 98.31% (APTIMA), respectively. Participants expressed a preference for tampon self-collection over HCW-collected swabs (90%). Conclusion: Self-collected tampons demonstrated promising diagnostic accuracy to HCW-collected swabs for HPV and STI detection. The tampon self-collection method was well-accepted and preferred by participants, suggesting its potential as an alternative screening tool, particularly in low-resource settings. Further research with larger and more diverse populations is recommended to validate these findings and inform tampon-based self-collection programs for cervical cancer screening. Randomised controlled trials and comparisons with gold standard methods would enhance validation.